ALT5 Sigma Corporation reported record Q3 2024 financial results, with fintech segment revenue reaching $4.94 million. The company achieved a gross profit of $2.39 million and adjusted EBITDA of $890,000 in its fintech division. Transaction volume exceeded $600 million for the quarter.CEO Peter Tassiopoulos highlighted strong customer onboarding and deeper client engagements. The company plans to expand services and prepare for geographic growth in anticipation of new opportunities. ALT5 Sigma is also making progress on separating its biotech business, Alyea Therapeutics, with completion expected in the first half of 2025.Recent developments include changing the company name from JanOne Inc. to ALT5 Sigma Corporation, appointing Peter Tassiopoulos as CEO, and adding Ron Pitters to the Board. The company also acquired third-party intellectual property to accelerate the launch of new features for ALT5 Prime and ALT5 Pay in Q4 2024 and Q1 2025.

ALT5 Sigma Corporation reported record Q3 2024 financial results, with fintech segment revenue reaching $4.94 million. The company achieved a gross profit of $2.39 million and adjusted EBITDA of $890,000 in its fintech division. Transaction volume exceeded $600 million for the quarter.CEO Peter Tassiopoulos highlighted strong customer onboarding and deeper client engagements. The company plans to expand services and prepare for geographic growth in anticipation of new opportunities. ALT5 Sigma is also making progress on separating its biotech business, Alyea Therapeutics, with completion expected in the first half of 2025.Recent developments include changing the company name from JanOne Inc. to ALT5 Sigma Corporation, appointing Peter Tassiopoulos as CEO, and adding Ron Pitters to the Board. The company also acquired third-party intellectual property to accelerate the launch of new features for ALT5 Prime and ALT5 Pay in Q4 2024 and Q1 2025.